Tianjin's RMB 30 Billion Biomedical Industry Expands Innovative Capacity
This article was originally published in PharmAsia News
Executive SummaryTianjin's biomedical industry output value in 2009 exceeded RMB 30 million, boosted by significant gains in innovative capacity in recent years
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.